OSE Immunotherapeutics: Tedopi Selected for Presentation at ASCO 2026
OSE Immunotherapeutics announces the selection of its Phase 2 TEDOVA clinical trial results for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Congress, to be held in Chicago from May 29 to June 2, 2026. This trial evaluates Tedopi® as a maintenance treatment for ovarian cancer.
Overview of the TEDOVA Phase 2 Study
The Phase 2 TEDOVA study, promoted by ARCAGY-GINECO, evaluates Tedopi® either as a monotherapy or in combination with pembrolizumab (Keytruda®), compared to standard care. The trial involves 185 patients with platinum-sensitive recurrent ovarian cancer, whose disease is controlled after platinum-based chemotherapy and who have previously received treatment with bevacizumab and a PARP inhibitor. The primary endpoint is progression-free survival (PFS) from maintenance treatment with Tedopi® in combination with a PD1 inhibitor after platinum-based chemotherapy. The study is also identified under the numbers GINECO-OV244b and ENGOT-ov58 (NCT04713514).
Presentation Details
The oral presentation will be conducted by Professor Alexandra Leary, Deputy Head of the Oncology Medicine Department at Gustave Roussy, Chair of the GINECO group, and Principal Investigator of the TEDOVA study. The presentation is scheduled for May 30, 2026, from 3:06 PM to 3:12 PM CEST (8:06 AM to 8:12 AM CDT) in room E450, during the Gynecologic Cancer session, Ovarian Cancer sub-session (Abstract 5510).
